Earnings call transcript: BioRestorative Therapies Q1 2025 sees widened losses
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerns: a significant revenue decline, increased net loss, and operational losses, along with uncertainties in clinical trials and market competition. Despite a strong cash position, these issues overshadow positive aspects like the FDA's Fast Track designation and potential patient recruitment improvements. The Q&A section highlights management's unclear responses, particularly regarding interim analysis, adding to investor uncertainty. Given these factors, the stock is likely to experience a negative reaction, reflecting investor concerns over financial performance and strategic execution.
Key Financial Performance
Revenue $25,000 compared to $35,000 in the same period last year, a decrease of approximately 29%. The decrease was attributed to a timing difference on when revenue was booked versus when it was received.
Deferred Revenue $150,000 compared to nil in the first quarter of 2024. This increase reflects a timing difference in revenue recognition.
Loss from Operations $4,800,000 compared to $4,100,000 for the comparable period in 2024, an increase of approximately 17%. This increase was not detailed in the transcript.
Net Loss $5,300,000 or $0.64 per share compared to a net loss of $2,200,000 or $0.33 per share for the first quarter of 2024, an increase of approximately 141%. The change was primarily due to a gain on the exchange of warrants in Q1 2024.
Cash Used in Operating Activities $2,800,000 for the first quarter of 2025, no year-over-year comparison was provided.
Cash, Cash Equivalents and Marketable Securities $9,100,000 as of 03/31/2025, with no outstanding debt, indicating a strong financial position.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
BRTX-one hundred: A novel cell-based therapeutic targeting areas with little or no blood flow, currently in a Phase II trial for chronic lumbar disc disease (CLDD). FDA granted Fast Track designation for this program.
ThermoStem: A preclinical metabolic program developing cell-based therapies for obesity and metabolic disorders using brown adipose-derived stem cells.
FDA clearance: FDA cleared the investigational new drug application for a Phase II trial of BRTX-one hundred in chronic cervical discogenic pain (CCDP), making it the first stem cell product candidate cleared for this indication.
Financial Position: As of March 31, 2025, the company had cash, cash equivalents, and marketable securities of $9,100,000 with no outstanding debt.
Revenue: First quarter 2025 revenues were $25,000, down from $35,000 in the same period last year.
Intellectual Property: Expanded patent portfolio for ThermoStem to ensure long-term market exclusivity and ongoing discussions for potential licensing agreements.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Financial Performance Risks: The company reported a net loss of $5,300,000 for Q1 2025, an increase from $2,200,000 in Q1 2024, indicating potential financial instability.
Regulatory Risks: The company is navigating FDA regulations for its clinical trials, which may impact timelines and outcomes. The need for ongoing discussions with the FDA regarding trial endpoints and data management adds uncertainty.
Clinical Trial Risks: The ongoing Phase II trial for BRTX-one hundred faces challenges in patient recruitment due to strict criteria for discogenic pain, which may affect enrollment rates.
Market Competition Risks: The company is in a competitive landscape for regenerative medicine, necessitating a strong patent portfolio to protect its innovations and market position.
Economic Factors: The overall economic environment may impact funding and investment in biotech, which could affect the company's operational capabilities and growth.
Supply Chain Risks: Challenges in sourcing materials for clinical trials and product development could hinder progress and increase costs.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
BRTX-one hundred Clinical Program: The FDA granted Fast Track designation for BRTX-one hundred, facilitating development and review of the investigational treatment for chronic lumbar disc disease (CLDD).
Cervical Disc Degeneration Trial: The FDA cleared the investigational new drug application for a phase two clinical trial for BRTX-one hundred in chronic cervical discogenic pain (CCDP), making it the first stem cell-based product candidate cleared for this indication.
ThermoStem Program: Continuing discussions with a commercial stage regenerative medicine company regarding a potential license agreement for ThermoStem metabolic disease programs.
Intellectual Property Expansion: The company is expanding its patent portfolio to ensure long-term market exclusivity for its products.
Financial Position: As of March 31, 2025, the company had cash, cash equivalents, and marketable securities of $9,100,000 with no outstanding debt.
Revenue Expectations: First quarter 2025 revenues were $25,000, a decrease from $35,000 in the same period last year, with deferred revenues of $150,000.
Operational Loss: First quarter 2025 loss from operations was $4,800,000, compared to $4,100,000 for the same period in 2024.
Future Data Presentation: The company intends to present more data from the BRTX-one hundred trial with a larger patient population soon, remaining optimistic about consistent positive trends.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cash Position: The company ended the quarter with cash, cash equivalents, and marketable securities of $9,100,000.
Debt Status: The company has no outstanding debt.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:You call the efficacy endpoint of greater than or equal to 30% improvement, a preliminary endpoint. Is that some kind of foreshadowing that the endpoint that you’re gonna have to hit is no longer gonna be greater than or equal to 30 and more, like, greater than or equal to 50?
A:No, we’re not changing the endpoint. It’s still both just a 30% improvement. The word preliminary is there as meaning that it’s not the primary. The primary endpoint is safety of the study.
Q:I noticed in the second slide presentation, last week’s versus February, there was no more line about potential interim analysis at twenty six weeks. So is that out, or will that still be performed?
A:We haven’t determined that we’re going to do an interim. It’s a potential and that’s still something that’s on the table as an option.
Q:And the last one is the 45 subject data being presented in HK or China, where are those 45 patients coming from?
A:From the current study. So these are patients that have already been dosed and are at different time points within the visitation and the weeks.
Q:In terms of speed of enrollment, do you expect enrollment to continue at its current pace? Kind of what is that pace?
A:No, actually, I think just the reverse. We’re starting to see a real uptick in patients because of some of the strategies that we’ve been employed from a recruitment perspective.
Q:Has there been more emphasis from FDA on pain or function? Or did they want to see both, reduction of pain with functional improvement?
A:We haven’t had specific feedback that, for example, function would be dropped from the protocol.
Q:Have you provided any additional enrollment or patient characteristics or the patients older, younger, middle age? Where do you think you’re seeing the most response potentially?
A:We do have younger patients that are in their early 20s, but then again, we have older patients that are in their late 50s.
Q:Can you discuss a little bit more about what was observed regarding morphological changes in response to the cells?
A:It’s very encouraging to see these morphological changes. For example, in one subject, at fifty two weeks compared to baseline using the same MRI magnet, we see that there’s increased hydration.
Q:Do you think with more mature morphological data that that could be supplemental in your data package to FDA ultimately and maybe even reduce the size of what could be a registration study next?
A:We believe so. We really don’t wanna compromise how we could use this potential data going forward.
Q:Review of Unclear Management Responses
A:Management did not provide a clear answer regarding the potential interim analysis at twenty six weeks, stating it is still on the table but has not been determined.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alspot Chairman
BRTX product
China patient
Development BioRestorative
FDA communication
FDA discussion
FDA emphasis
FDA host
FDA question
Lance Alspot
Officer BioRestorative
Therapies patient
Therapies week
analysis
case
criterion
decrease
efficacy endpoint
endpoint efficacy
endpoint improvement
enrollment patient
environment
example
feedback
function
hydration
order
pace
past
patient Vice
protocol
protrusion
recruitment
response
signal
size
strategy
summer
table
tear week
week Vice
week presentation
word
BRTX Transcript
BioRestorative Therapies, Inc. (BRTX) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call reveals significant financial challenges, including a drastic revenue decline and increased losses. The heavy dependence on clinical trials, regulatory risks, and cash burn further exacerbate concerns. Additionally, management's lack of clarity on revenue guidance and FDA timelines adds uncertainty. Despite the large market potential for BioCosmeceuticals, the absence of clear revenue projections and reliance on partnerships indicate strategic vulnerabilities. The overall sentiment from the call and Q&A is negative, suggesting a strong negative stock price reaction over the next two weeks.
Earnings call transcript: BioRestorative Therapies Q1 2025 sees widened losses
Unknown5-14
The earnings call reveals several concerns: a significant revenue decline, increased net loss, and operational losses, along with uncertainties in clinical trials and market competition. Despite a strong cash position, these issues overshadow positive aspects like the FDA's Fast Track designation and potential patient recruitment improvements. The Q&A section highlights management's unclear responses, particularly regarding interim analysis, adding to investor uncertainty. Given these factors, the stock is likely to experience a negative reaction, reflecting investor concerns over financial performance and strategic execution.
BioRestorative Therapies, Inc. (BRTX) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call reveals several concerning factors: a significant increase in net loss, decreased revenue, and a rise in operational costs. Despite positive deferred revenue and no debt, financial instability is evident. The Q&A section highlights uncertainties, particularly regarding clinical trials and regulatory risks. No share repurchase program is announced, and market competition remains a threat. These factors, combined with the absence of strong positive catalysts, suggest a likely negative stock price movement over the next two weeks.
BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Call Transcript
Unknown3-27
The earnings call summary shows strong revenue growth and improved financial metrics, but the company still faces significant risks, including regulatory uncertainties and financial losses. The Q&A session highlighted management's cautious responses regarding trial enrollment and cash burn, suggesting potential uncertainties. The lack of a shareholder return plan and the competitive landscape further contribute to a neutral sentiment. Despite positive developments like FDA Fast Track designation, the absence of immediate catalysts and ongoing challenges balance the overall outlook.
BRTX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
